FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4234734983> ?p ?o ?g. }

• W4234734983 endingPage "31" @default.
• W4234734983 startingPage "28" @default.
• W4234734983 abstract "Background: Bacitracin is widely used for the treatment and prevention of superficial skin infections. Although commonly used, anaphylaxis to topically applied bacitracin is rare, with only nine previously reported cases. Most reported reactions have occurred in middle-aged to elderly women with leg ulcers or chronic eczema. Although most reports include a challenge test to confirm the diagnosis, no recommended standardized method of skin testing for bacitracin anaphylaxis has been advocated to date. Objective: We report two patients who developed anaphylaxis to topically applied bacitracin ointment confirmed by skin prick testing. The subject of bacitracin anaphylaxis is reviewed, and a method for confirmatory skin testing is recommended. Methods: Literature was searched in the MEDLINE database using the key words anaphylaxis and bacitracin, and articles from theAmerican Journal of Contact Dermatitiswere also included. Relevant references from these reports were also reviewed. Percutaneous skin prick testing was performed on our 2 patients using the bacitracin powder dilution (10 U/mL and 1 U/mL). Normal control individuals were also tested. Results: Two patients with anaphylaxis to bacitracin are reported. One developed symptoms after a biopsy of chronic eczema was performed. The second patient had no prior history of chronic skin disease and developed symptoms after incurring an abrasion on his knee. The diagnosis was confirmed by a positive wheal and flare reaction after skin prick testing at 1 U/mL and 10 U/mL concentrations, respectively. Normal controls showed no wheal and flare reaction at 10 U/mL. Conclusions: Anaphylaxis to topical bacitracin is rare but potentially fatal. Based on our literature review and the results of our skin testing, we recommend initiating future bacitracin prick testing with 0.1 U/mL. If no reaction occurs at this dilution, subsequent prick testing should be serially performed with a 10-fold higher concentration. Each test should be separated by 15 minutes to a maximum concentration of 10 U/mL. Testing at higher concentrations or by the intradermal method may lead to a false-positive test.This is a US government work. There are no restrictions on its use." @default.
• W4234734983 created "2022-05-12" @default.
• W4234734983 creator A5029615313 @default.
• W4234734983 creator A5033184432 @default.
• W4234734983 creator A5056900106 @default.
• W4234734983 creator A5058945196 @default.
• W4234734983 creator A5061857619 @default.
• W4234734983 date "1995-03-01" @default.
• W4234734983 modified "2023-09-28" @default.
• W4234734983 title "Anaphylaxis to Topically Applied Bacitracin" @default.
• W4234734983 doi "https://doi.org/10.1097/01206501-199503000-00008" @default.
• W4234734983 hasPublicationYear "1995" @default.
• W4234734983 type Work @default.
• W4234734983 citedByCount "0" @default.
• W4234734983 crossrefType "journal-article" @default.
• W4234734983 hasAuthorship W4234734983A5029615313 @default.
• W4234734983 hasAuthorship W4234734983A5033184432 @default.
• W4234734983 hasAuthorship W4234734983A5056900106 @default.
• W4234734983 hasAuthorship W4234734983A5058945196 @default.
• W4234734983 hasAuthorship W4234734983A5061857619 @default.
• W4234734983 hasConcept C16005928 @default.
• W4234734983 hasConcept C203014093 @default.
• W4234734983 hasConcept C207480886 @default.
• W4234734983 hasConcept C2775933838 @default.
• W4234734983 hasConcept C2778570526 @default.
• W4234734983 hasConcept C2779121184 @default.
• W4234734983 hasConcept C2779860364 @default.
• W4234734983 hasConcept C501593827 @default.
• W4234734983 hasConcept C71924100 @default.
• W4234734983 hasConcept C86803240 @default.
• W4234734983 hasConcept C89423630 @default.
• W4234734983 hasConceptScore W4234734983C16005928 @default.
• W4234734983 hasConceptScore W4234734983C203014093 @default.
• W4234734983 hasConceptScore W4234734983C207480886 @default.
• W4234734983 hasConceptScore W4234734983C2775933838 @default.
• W4234734983 hasConceptScore W4234734983C2778570526 @default.
• W4234734983 hasConceptScore W4234734983C2779121184 @default.
• W4234734983 hasConceptScore W4234734983C2779860364 @default.
• W4234734983 hasConceptScore W4234734983C501593827 @default.
• W4234734983 hasConceptScore W4234734983C71924100 @default.
• W4234734983 hasConceptScore W4234734983C86803240 @default.
• W4234734983 hasConceptScore W4234734983C89423630 @default.
• W4234734983 hasIssue "1" @default.
• W4234734983 hasLocation W42347349831 @default.
• W4234734983 hasOpenAccess W4234734983 @default.
• W4234734983 hasPrimaryLocation W42347349831 @default.
• W4234734983 hasRelatedWork W1598094745 @default.
• W4234734983 hasRelatedWork W1997902911 @default.
• W4234734983 hasRelatedWork W2002381403 @default.
• W4234734983 hasRelatedWork W2040862434 @default.
• W4234734983 hasRelatedWork W2043231538 @default.
• W4234734983 hasRelatedWork W2051362673 @default.
• W4234734983 hasRelatedWork W2225877035 @default.
• W4234734983 hasRelatedWork W2405018052 @default.
• W4234734983 hasRelatedWork W2433317387 @default.
• W4234734983 hasRelatedWork W3032171527 @default.
• W4234734983 hasVolume "6" @default.
• W4234734983 isParatext "false" @default.
• W4234734983 isRetracted "false" @default.
• W4234734983 workType "article" @default.